Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in:

Open Access 01-12-2017 | Review

The role of cullin4B in human cancers

Authors: Ying Li, Xin Wang

Published in: Experimental Hematology & Oncology | Issue 1/2017

Login to get access

Abstract

Cullin 4B (CUL4B) is a scaffold of the Cullin4B-Ring E3 ligase complex (CRL4B) that plays an important role in proteolysis and is implicated in tumorigenesis. Aberrant expression of CUL4B has been reported in various types of human diseases. Recently, studies have shown that CUL4B was overexpressed in a multitude of solid neoplasms and affect the expression of several tumor suppressor genes. In this review, we aim to summarize the biological function of CUL4B in order to better understand its pathogenesis in human cancers.
Literature
1.
2.
3.
Hu H, Yang Y, Ji Q, Zhao W, Jiang B, Liu R, Yuan J, Liu Q, Li X, Zou Y, et al. CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis. Cancer Cell. 2012;22(6):781–95.CrossRefPubMed
4.
He F, Lu D, Jiang B, Wang Y, Liu Q, Liu Q, Shao C, Li X, Gong Y. X-linked intellectual disability gene CUL4B targets Jab1/CSN5 for degradation and regulates bone morphogenetic protein signaling. Biochim Biophys Acta. 2013;1832(5):595–605.CrossRefPubMed
5.
Zou Y, Mi J, Cui J, Lu D, Zhang X, Guo C, Gao G, Liu Q, Chen B, Shao C, et al. Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression. J Biol Chem. 2009;284(48):33320–32.CrossRefPubMedPubMedCentral
6.
7.
Chen CY, Tsai MS, Lin CY, Yu IS, Chen YT, Lin SR, Juan LW, Chen YT, Hsu HM, Lee LJ, et al. Rescue of the genetically engineered Cul4b mutant mouse as a potential model for human X-linked mental retardation. Hum Mol Genet. 2012;21(19):4270–85.CrossRefPubMed
8.
Zou Y, Mi J, Wang W, Lu J, Zhao W, Liu Z, Hu H, Yang Y, Gao X, Jiang B, et al. CUL4B promotes replication licensing by up-regulating the CDK2-CDC6 cascade. J Cell Biol. 2013;200(6):743–56.CrossRefPubMedPubMedCentral
9.
Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, Kouzmenko A, Nohara K, Chiba T, et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature. 2007;446(7135):562–6.CrossRefPubMed
10.
Li X, Lu D, He F, Zhou H, Liu Q, Wang Y, Shao C, Gong Y. Cullin 4B protein ubiquitin ligase targets peroxiredoxin III for degradation. J Biol Chem. 2011;286(37):32344–54.CrossRefPubMedPubMedCentral
11.
Nakagawa T, Xiong Y. X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression. Mol Cell. 2011;43(3):381–91.CrossRefPubMedPubMedCentral
12.
Jiang B, Zhao W, Yuan J, Qian Y, Sun W, Zou Y, Guo C, Chen B, Shao C, Gong Y. Lack of Cul4b, an E3 ubiquitin ligase component, leads to embryonic lethality and abnormal placental development. PLoS ONE. 2012;7(5):e37070.CrossRefPubMedPubMedCentral
13.
Liu L, Yin Y, Li Y, Prevedel L, Lacy EH, Ma L, Zhou P. Essential role of the CUL4B ubiquitin ligase in extra-embryonic tissue development during mouse embryogenesis. Cell Res. 2012;22(8):1258–69.CrossRefPubMedPubMedCentral
14.
Liu L, Lee S, Zhang J, Peters SB, Hannah J, Zhang Y, Yin Y, Koff A, Ma L, Zhou P. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell. 2009;34(4):451–60.CrossRefPubMedPubMedCentral
15.
Yin Y, Lin C, Kim ST, Roig I, Chen H, Liu L, Veith GM, Jin RU, Keeney S, Jasin M, et al. The E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis. Dev Biol. 2011;356(1):51–62.CrossRefPubMedPubMedCentral
16.
17.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.CrossRefPubMed
18.
Mi J, Zou Y, Lin X, Lu J, Liu X, Zhao H, Ye X, Hu H, Jiang B, Han B, et al. Dysregulation of the miR-194-CUL4B negative feedback loop drives tumorigenesis in non-small-cell lung carcinoma. Mol Oncol. 2017;11:305–19.CrossRefPubMed
19.
Yuan J, Han B, Hu H, Qian Y, Liu Z, Wei Z, Liang X, Jiang B, Shao C, Gong Y. CUL4B activates Wnt/beta-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists. J Pathol. 2015;235(5):784–95.CrossRefPubMed
20.
Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H, Ji Q, He H, Shang Y, Gong Y, et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene. 2015;34(1):104–18.CrossRefPubMed
21.
Chen Z, Shen BL, Fu QG, Wang F, Tang YX, Hou CL, Chen L. CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells. Oncol Rep. 2014;32(5):2047–53.PubMed
22.
Tarpey PS, Raymond FL, O’Meara S, Edkins S, Teague J, Butler A, Dicks E, Stevens C, Tofts C, Avis T, et al. Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor. Am J Hum Genet. 2007;80(2):345–52.CrossRefPubMedPubMedCentral
23.
Zou Y, Liu Q, Chen B, Zhang X, Guo C, Zhou H, Li J, Gao G, Guo Y, Yan C, et al. Mutation in CUL4B, which encodes a member of cullin-RING ubiquitin ligase complex, causes X-linked mental retardation. Am J Hum Genet. 2007;80(3):561–6.CrossRefPubMedPubMedCentral
24.
25.
Vulto-van Silfhout AT, Nakagawa T, Bahi-Buisson N, Haas SA, Hu H, Bienek M, Vissers LE, Gilissen C, Tzschach A, Busche A, et al. Variants in CUL4B are associated with cerebral malformations. Hum Mutat. 2015;36(1):106–17.CrossRefPubMedPubMedCentral
26.
Dong J, Wang XQ, Yao JJ, Li G, Li XG. Decreased CUL4B expression inhibits malignant proliferation of glioma in vitro and in vivo. Eur Rev Med Pharmacol Sci. 2015;19(6):1013–21.PubMed
27.
Jiang T, Tang HM, Wu ZH, Chen J, Lu S, Zhou CZ, Yan DW, Peng ZH. Cullin 4B is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Med Oncol. 2013;30(2):534.CrossRefPubMed
28.
Wang X, Chen Z. Knockdown of CUL4B Suppresses the proliferation and invasion in non-small cell lung cancer cells. Oncol Res. 2016;24(4):271–7.CrossRefPubMed
29.
Hannah J, Zhou P. Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases. DNA Repair (Amst). 2009;8(4):536–43.CrossRef
30.
Moss J, Tinline-Purvis H, Walker CA, Folkes LK, Stratford MR, Hayles J, Hoe KL, Kim DU, Park HO, Kearsey SE, et al. Break-induced ATR and Ddb1-Cul4(Cdt)(2) ubiquitin ligase-dependent nucleotide synthesis promotes homologous recombination repair in fission yeast. Genes Dev. 2010;24(23):2705–16.CrossRefPubMedPubMedCentral
31.
Kerzendorfer C, Whibley A, Carpenter G, Outwin E, Chiang SC, Turner G, Schwartz C, El-Khamisy S, Raymond FL, O’Driscoll M. Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks. Hum Mol Genet. 2010;19(7):1324–34.CrossRefPubMedPubMedCentral
32.
Guerrero-Santoro J, Kapetanaki MG, Hsieh CL, Gorbachinsky I, Levine AS, Rapic-Otrin V. The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-damaged chromatin and ubiquitinates histone H2A. Cancer Res. 2008;68(13):5014–22.CrossRefPubMed
33.
Yi J, Lu G, Li L, Wang X, Cao L, Lin M, Zhang S, Shao G. DNA damage-induced activation of CUL4B targets HUWE1 for proteasomal degradation. Nucleic Acids Res. 2015;43(9):4579–90.CrossRefPubMedPubMedCentral
34.
Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079–93.CrossRefPubMed
35.
Gallastegui E, Bachs O. Expression and purification of recombinant cyclins and CDKs for activity evaluation. Methods Mol Biol. 2016;1336:9–12.CrossRefPubMed
36.
Stein GS, van Wijnen AJ, Stein JL, Lian JB, Montecino M, Zaidi SK, Braastad C. An architectural perspective of cell-cycle control at the G1/S phase cell-cycle transition. J Cell Physiol. 2006;209(3):706–10.CrossRefPubMed
37.
Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, et al. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017;8:14897.PubMedPubMedCentral
38.
Boueroy P, Hahnvajanawong C, Boonmars T, Saensa-Ard S, Anantachoke N, Vaeteewoottacharn K, Reutrakul V. Antitumor effect of forbesione isolated from Garcinia hanburyi on cholangiocarcinoma in vitro and in vivo. Oncol Lett. 2016;12(6):4685–98.PubMedPubMedCentral
39.
Li W, Zhang G, Wang HL, Wang L. Analysis of expression of cyclin E, p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis, treatment and prognosis of disease. Eur Rev Med Pharmacol Sci. 2016;20(23):4874–9.PubMed
40.
Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, Chiba T. Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers. Int J Cancer. 2009;125(9):2029–35.CrossRefPubMed
41.
Siu KT, Xu Y, Swartz KL, Bhattacharyya M, Gurbuxani S, Hua Y, Minella AC. Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-mediated cyclin E regulation. Mol Cell Biol. 2014;34(17):3244–58.CrossRefPubMedPubMedCentral
42.
Higa LA, Yang X, Zheng J, Banks D, Wu M, Ghosh P, Sun H, Zhang H. Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27Kip1 and cyclin E degradation. Cell Cycle. 2006;5(1):71–7.CrossRefPubMed
43.
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 1995;377(6549):552–7.CrossRefPubMed
44.
Ji Q, Hu H, Yang F, Yuan J, Yang Y, Jiang L, Qian Y, Jiang B, Zou Y, Wang Y, et al. CRL4B interacts with and coordinates the SIN3A-HDAC complex to repress CDKN1A and drive cell cycle progression. J Cell Sci. 2014;127(Pt 21):4679–91.CrossRefPubMed
45.
46.
Chen Z, Li S, Subramaniam S, Shyy JY, Chien S. Epigenetic regulation: a new frontier for biomedical engineers. Annu Rev Biomed Eng. 2017.
47.
Fu M, Rao M, Wu K, Wang C, Zhang X, Hessien M, Yeung YG, Gioeli D, Weber MJ, Pestell RG. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem. 2004;279(28):29436–49.CrossRefPubMed
48.
Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci. 2001;58(5–6):728–36.CrossRefPubMed
49.
Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Epigenetic control of gene expression: potential implications for cancer treatment. Crit Rev Oncol Hematol. 2017;111:166–72.CrossRefPubMed
50.
51.
Bai D, Yu S, Zhong S, Zhao B, Qiu S, Chen J, Lunagariya J, Liao X, Xu S. d-amino acid position influences the anticancer activity of galaxamide analogs: an apoptotic mechanism study. Int J Mol Sci. 2017;18(3):544.CrossRefPubMedCentral
52.
53.
Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget. 2015;6(20):17873–90.CrossRefPubMedPubMedCentral
54.
Song B, Zhan H, Bian Q, Li J. Knockdown of CUL4B inhibits proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/beta-catenin signaling pathway. Int J Clin Exp Pathol. 2015;8(9):10394–402.PubMedPubMedCentral
55.
Shan Y, Ying R, Jia Z, Kong W, Wu Y, Zheng S, Jin H. LINC00052 promotes gastric cancer cell proliferation and metastasis via activating Wnt/beta-catenin signaling pathway. Oncol Res. 2017.
56.
Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012;336(6088):1549–54.CrossRefPubMed
57.
Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science. 2002;296(5573):1644–6.CrossRefPubMed
58.
Ghosh P, Wu M, Zhang H, Sun H. mTORC1 signaling requires proteasomal function and the involvement of CUL4-DDB1 ubiquitin E3 ligase. Cell Cycle. 2008;7(3):373–81.CrossRefPubMed
59.
Qian Y, Yuan J, Hu H, Yang Q, Li J, Zhang S, Jiang B, Shao C, Gong Y. The CUL4B/AKT/beta-catenin axis restricts the accumulation of myeloid-derived suppressor cells to prohibit the establishment of a tumor-permissive microenvironment. Cancer Res. 2015;75(23):5070–83.CrossRefPubMed
60.
Badura-Stronka M, Jamsheer A, Materna-Kiryluk A, Sowińska A, Kiryluk K, Budny B, Latos‐Bieleńska A. A novel nonsense mutation inCUL4Bgene in three brothers with X-linked mental retardation syndrome. Clin Genet. 2010;77(2):141–4.CrossRefPubMed
61.
Wang HL, Chang NC, Weng YH, Yeh TH. XLID CUL4B mutants are defective in promoting TSC2 degradation and positively regulating mTOR signaling in neocortical neurons. Biochim Biophys Acta. 2013;1832(4):585–93.CrossRefPubMed
62.
Yin Y, Liu L, Yang C, Lin C, Veith GM, Wang C, Sutovsky P, Zhou P, Ma L. Cell autonomous and nonautonomous function of CUL4B in mouse spermatogenesis. J Biol Chem. 2016;291(13):6923–35.CrossRefPubMedPubMedCentral
63.
Kerzendorfer C, Hart L, Colnaghi R, Carpenter G, Alcantara D, Outwin E, Carr AM, O’Driscoll M. CUL4B-deficiency in humans: understanding the clinical consequences of impaired Cullin 4-RING E3 ubiquitin ligase function. Mech Ageing Dev. 2011;132(8–9):366–73.CrossRefPubMed
64.
Cang Y, Zhang J, Nicholas SA, Bastien J, Li B, Zhou P, Goff SP. Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell. 2006;127(5):929–40.CrossRefPubMed
65.
Pan WW, Zhou JJ, Yu C, Xu Y, Guo LJ, Zhang HY, Zhou D, Song FZ, Fan HY. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer. J Biol Chem. 2013;288(41):29680–91.CrossRefPubMedPubMedCentral
66.
Yuan J, Jiang B, Zhang A, Qian Y, Tan H, Gao J, Shao C, Gong Y. Accelerated hepatocellular carcinoma development in CUL4B transgenic mice. Oncotarget. 2015;6(17):15209–21.CrossRefPubMedPubMedCentral
67.
Mok MT, Cheng AS. CUL4B: a novel epigenetic driver in Wnt/beta-catenin-dependent hepatocarcinogenesis. J Pathol. 2015;236(1):1–4.CrossRefPubMed
68.
Qu Z, Li D, Xu H, Zhang R, Li B, Sun C, Dong W, Zhang Y. CUL4B, NEDD4, and UGT1As involve in the TGF-beta signalling in hepatocellular carcinoma. Ann Hepatol. 2016;15(4):568–76.PubMed
69.
Jia L, Yan F, Cao W, Chen Z, Zheng H, Li H, Pan Y, Narula N, Ren X, Li H, et al. Dysregulation of CUL4A and CUL4B ubiquitin ligases in lung cancer. J Biol Chem. 2017;292(7):2966–78.CrossRefPubMed
Metadata
Title
The role of cullin4B in human cancers
Authors
Ying Li
Xin Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2017
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/s40164-017-0077-2

Other articles of this Issue 1/2017

The development of bispecific antibodies and their applications in tumor immune escape

  • Open Access
  • Review

A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises

  • Open Access
  • Research

Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission

  • Open Access
  • Case report

Pivotal regulators of tissue homeostasis and cancer: macrophages

  • Open Access
  • Review

PTEN is a negative regulator of mitotic checkpoint complex during the cell cycle

  • Open Access
  • Research

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

  • Open Access
  • Case report

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits